YOU ARE HERE:
Most HIV/HBV co-infected patients in Europe have detectable HBV viral load
Only a third of HIV-positive patients co-infected with chronic hepatitis B virus in Europe have an undetectable hepatitis B viral load, according to a EuroSIDA study presented to the 12th European AIDS Conference in Cologne.
This low rate of undetectable hepatitis B viral load was despite the fact that approximately two-thirds of patients were taking antiretroviral therapy that included drugs with activity against hepatitis B.
HIV and hepatitis B share similar modes of transmission and a significant proportion of patients are co-infected with these viruses.
Factors associated with the progression of liver disease in co-infected patients include hepatitis B genotype and hepatitis B viral load.
Therefore investigators from the EuroSIDA cohort study analysed stored blood samples and patient notes to determine the epidemiological and clinical characteristics of chronic hepatitis B infection in these co-infected patients.
Of the 16,500 patients in the cohort, 7% (1200) had chronic hepatitis B infection and of these 484 had stored samples that were included in the study. These were obtained between 1994 and 2006.
Most of the patients were men (84%), Caucasian (85%) and gay (51%).
It was possible to determine hepatitis B genotype in 167 patients, the most common being genotype A. This genotype was found significantly more often in gay men than injecting drug users (p < 0.0001), and there was a trend for infections with this genotype to be found in Northern rather than Southern Europe (p = 0.054).
An undetectable hepatitis B viral load (below 357 copies iu/ml) was present in 34% of patients. Worryingly, 20% of patients had a viral load above 10,000,000 copies iu/ml, which is known to significantly increase the risk factor of cirrhosis and liver cancer.
Antiretroviral therapy was being taken by 90% of patients. A third of these individuals were taking a combination of drugs that had no activity against hepatitis B.
A third of patients taking 3TC had an undetectable hepatitis B viral load compared to 45% of those taking a combination including tenofovir (with or without 3TC or FTC). However, this difference was not significant. The investigators also noted that none of the patients taking this drug had a hepatitis B viral load above 10,000,000 copies iu/ml.
Statistical analysis showed that each doubling of baseline CD4 cell count significantly reduced the chances of having an undetectable hepatitis B viral load (p = 0.013). A total of 27% of patients were also co-infected with hepatitis C virus, and the investigators found that these patients were also more likely to have an undetectable hepatitis B viral load (p = 0.025).
Reference
Vogel M et al. Epidemiological and virological characteristics of chronic HBV infection in HIV-positive patients in Europe, 12th European AIDS Conference, Cologne, abstract PS2/2, 2009.
This low rate of undetectable hepatitis B viral load was despite the fact that approximately two-thirds of patients were taking antiretroviral therapy that included drugs with activity against hepatitis B.
HIV and hepatitis B share similar modes of transmission and a significant proportion of patients are co-infected with these viruses.
Factors associated with the progression of liver disease in co-infected patients include hepatitis B genotype and hepatitis B viral load.
Therefore investigators from the EuroSIDA cohort study analysed stored blood samples and patient notes to determine the epidemiological and clinical characteristics of chronic hepatitis B infection in these co-infected patients.
Of the 16,500 patients in the cohort, 7% (1200) had chronic hepatitis B infection and of these 484 had stored samples that were included in the study. These were obtained between 1994 and 2006.
Most of the patients were men (84%), Caucasian (85%) and gay (51%).
It was possible to determine hepatitis B genotype in 167 patients, the most common being genotype A. This genotype was found significantly more often in gay men than injecting drug users (p < 0.0001), and there was a trend for infections with this genotype to be found in Northern rather than Southern Europe (p = 0.054).
An undetectable hepatitis B viral load (below 357 copies iu/ml) was present in 34% of patients. Worryingly, 20% of patients had a viral load above 10,000,000 copies iu/ml, which is known to significantly increase the risk factor of cirrhosis and liver cancer.
Antiretroviral therapy was being taken by 90% of patients. A third of these individuals were taking a combination of drugs that had no activity against hepatitis B.
A third of patients taking 3TC had an undetectable hepatitis B viral load compared to 45% of those taking a combination including tenofovir (with or without 3TC or FTC). However, this difference was not significant. The investigators also noted that none of the patients taking this drug had a hepatitis B viral load above 10,000,000 copies iu/ml.
Statistical analysis showed that each doubling of baseline CD4 cell count significantly reduced the chances of having an undetectable hepatitis B viral load (p = 0.013). A total of 27% of patients were also co-infected with hepatitis C virus, and the investigators found that these patients were also more likely to have an undetectable hepatitis B viral load (p = 0.025).
Reference
Vogel M et al. Epidemiological and virological characteristics of chronic HBV infection in HIV-positive patients in Europe, 12th European AIDS Conference, Cologne, abstract PS2/2, 2009.
aidsmap resources
Conference news
- Household contact tracing reveals extensive community spread of MDR and XDR TB
- DetecTB study shows intensified case finding can reduce burden of TB within community with high HIV prevalence
- Partners in Health encourages better payment and training of community healthcare workers, reform of “clinical hierarchy”
Hepatitis news
feedback
Give us your views on our work